drugset / Trial / NCT02059239
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This clinical trial is for men and women with whose lymphoma (non-Hodgkin or Hodgkin) did not respond to treatment or has returned after responding to previous therapy, and who are in need of a stem cell transplant. The purpose of this study is to test the safety and effectiveness of giving the drug Bendamustine, followed by high dose chemotherapy, within two weeks prior to a stem cell transplant for lymphoma that has not achieved a complete response to salvage (treatment used for relapsed disease) chemotherapy.
Timeline
- Start
- 2014-06-04
- Primary completion
- 2019-12-16
- Completion
- 2020-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bendamustine | Small molecule | 200 mg/m2 | — |
| Background | Alemtuzumab | Monoclonal antibody | 20 mg/m2 | — |
| Background | Cytarabine | Small molecule | 200 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | carmustine | Small molecule | 300 mg/m2 | — |